Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 14 of 59, showing 10 Applications out of 584 total, starting on record 131, ending on 140

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

131.

ECCT/24/03/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL   
Principal Investigator(s)
1. Dr. Janet Nyawira Oyieko
Site(s) in Kenya
1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
 
14-05-2024 View

132.

ECCT/24/03/03   DoxyDOT Study
    Weekly doxycycline DOT for STI prevention among cisgender women taking HIV PrEP in Kisumu, Kenya   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
KEMRI CMR RCTP
 
31-05-2024 View

133.

ECCT/24/03/01   RAD-TB
    A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis   
Principal Investigator(s)
1. Dr Josphat Kosgei Kosgei
Site(s) in Kenya
Kenya medical research institute/ Walter Reed program KERICHO
 
26-11-2024 View

134.

ECCT/24/02/08   H06_02TP
    A Phase 2 single-blind, randomized, controlled, single center study to assess the immunogenicity and safety of a 2-dose schedule with GVGH altSonflex1-2-3 vaccine in African infants (H06_02TP)   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WRP CRC KERICHO
 
31-05-2024 View

135.

ECCT/24/02/07   CO-SAM
          An adaptive multi-arm trial to improve clinical outcomes among children recovering from complicated severe acute malnutrition (CO-SAM)             
Principal Investigator(s)
1. Benson Singa
Site(s) in Kenya
1. Homabay County Referral hospital (Homa Bay county)
2. Migori County Referral Hospital (Migori county)
3. Mbagathi County Referral Hospital (Nairobi City county)
4. Coast General Teaching and Referral Hospital (Mombasa county)
 
03-12-2024 View

136.

ECCT/24/04/04   TNBC
    A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF TOBEMSTOMIG/RO7247669 COMBINED WITH NAB-PACLITAXEL COMPARED WITH   PEMBROLIZUMAB COMBINED WITH NABPACLITAXEL IN PARTICIPANTS WITH PREVIOUSLY UNTREATED, PD-L1-POSITIVE, LOCALLY-ADVANCED UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
1. University of Nairobi - Institute of Tropical and Infectious Diseases (Nairobi City county)
2. International Cancer Institute (Nandi county)
3. The Aga Khan University Hospital - Kenya (Nairobi City county)
 
19-09-2024 View

137.

ECCT/24/02/10   IMBrave
    A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA   
Principal Investigator(s)
1. Dr. Pauline Njoki Njiraini
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
09-06-2024 View

138.

ECCT/24/02/04   IGHID 12333
    IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.   
Principal Investigator(s)
1. Chemtai Mungo
Site(s) in Kenya
Lumumba subcounty Hospital Kisumu
 
26-04-2024 View

139.

ECCT/24/02/02   Sabin 003
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults   
Principal Investigator(s)
1. Prof. Videlis Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
23-04-2024 View

140.

ECCT/24/02/06   INAVO122
    A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
03-07-2024 View